Details for Patent: 11,931,350
✉ Email this page to a colleague
Which drugs does patent 11,931,350 protect, and when does it expire?
Patent 11,931,350 protects OLINVYK and is included in one NDA.
This patent has fifty-one patent family members in twenty-three countries.
Drugs Protected by US Patent 11,931,350
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-001 | Oct 30, 2020 | RX | Yes | Yes | 11,931,350 | ⤷ Subscribe | Y | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION | ⤷ Subscribe | |||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-002 | Oct 30, 2020 | RX | Yes | Yes | 11,931,350 | ⤷ Subscribe | Y | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION | ⤷ Subscribe | |||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-003 | Oct 30, 2020 | RX | Yes | Yes | 11,931,350 | ⤷ Subscribe | Y | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,931,350
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012230761 | ⤷ Subscribe | |||
| Australia | 2017200745 | ⤷ Subscribe | |||
| Brazil | 112013024136 | ⤷ Subscribe | |||
| Canada | 2830742 | ⤷ Subscribe | |||
| China | 103702561 | ⤷ Subscribe | |||
| Cyprus | 1119057 | ⤷ Subscribe | |||
| Denmark | 2688403 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
